13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002010850
Total reported value
$731.7M
$731.7M
14 檔
81.6%
During the Q1 2026 filing period, Decheng Capital LLC (CIK: 0002010850) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $731.7M across 14 reported positions.
In Q1 2026, Decheng Capital LLC adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 5 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 65.21% | -3.34% | — | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 16.84% | +3.31% | — | |
| 3 | UPB | Upstream Bio Inc | Stock-Other | 3.71% | -1.13% | -13.31% | |
| 4 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 2.29% | +0.63% | — | |
| 5 | AARD | Aardvark Therapeutics Inc | Stock-Other | 2.23% | +0.85% | — | |
| 6 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 2.10% | -0.77% | — | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.57% | -0.75% | -45.10% | |
| 8 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.56% | +0.40% | -11.77% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.37% | -0.03% | -53.25% | |
| 10 | EQ | Equillium Inc | Stock-Other | 1.34% | +0.60% | — | |
| 11 | ✓ | Beyondspring Inc Shs | Stock-Other | 0.94% | -0.03% | — | |
| 12 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.47% | +0.41% | — | |
| 13 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.29% | -0.29% | EXIT | |
| 14 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.07% | +0.06% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | +29.6% | — | Unchanged |
| 2 | ACRS | Aclaris Therapeutics Inc | +0.7% | — | Unchanged |
| 3 | EQ | Equillium Inc | +0.4% | — | Unchanged |
| 4 | ZNTL | Zentalis Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 5 | ✓ | Beyondspring Inc Shs | +0.1% | — | Unchanged |
| 6 | PYXS | Pyxis Oncology Inc | 0% | — | Unchanged |
| 7 | RCUS | Arcus Biosciences Inc | -0.2% | -11.77% | Trim |
| 8 | KRYS | Krystal Biotech Inc | -0.3% | -57.80% | Trim |
| 9 | RVMD | Revolution Medicines Inc | -0.8% | -53.25% | Trim |
| 10 | LYEL | Lyell Immunopharma, Inc. | -0.8% | — | Unchanged |
| 11 | NAMS | NewAmsterdam Pharma Company N.V. | -1.2% | -45.10% | Trim |
| 12 | AARD | Aardvark Therapeutics Inc | -4.7% | — | Unchanged |
| 13 | UPB | Upstream Bio Inc | -7.8% | -13.31% | Trim |
| 14 | NUVB | Nuvation Bio Inc | -14.4% | — | Unchanged |
| 15 | CRNX | Crinetics Pharmaceuticals In | — | EXIT | Sold out |
| 16 | AURA | Aura Biosciences Inc | — | EXIT | Sold out |
| 17 | FDMT | 4d Molecular Therapeutics In | — | EXIT | Sold out |
| 18 | NUVB-WS | Nuvation Bio Inc -cw27 | — | EXIT | Sold out |
| 19 | RZLT | Rezolute Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Decheng Capital LLC reported a total U.S. public equity portfolio value of $731.7M across 14 disclosed positions in Q1 2026.
During Q1 2026, Decheng Capital LLC's top holdings by market value included CGON (65.2%)、NUVB (16.8%)、UPB (3.7%). The largest single position, CGON, represented 65.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, NUVB, UPB) accounted for 81.6% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
CRNX
前期市值: $4.3M
In Q1 2026, Decheng Capital LLC made 10 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 5 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.